No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NRXS Neuraxis
- 3.210
- -0.090-2.72%
Close May 3 16:00 ET
21.17MMarket Cap-1428P/E (TTM)
3.300High3.210Low6.66KVolume3.300Open3.300Pre Close21.84KTurnover0.18%Turnover RatioLossP/E (Static)6.59MShares6.93052wk High-15.07P/B12.03MFloat Cap1.80052wk Low--Dividend TTM3.75MShs Float6.930Historical High--Div YieldTTM2.73%Amplitude1.800Historical Low3.278Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NeurAxis Announces New Medical Policy Coverage In North Dakota
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressin
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript
NeurAxis Reports Q4 Results
Earnings Call Summary | Neuraxis(NRXS.US) Q4 2023 Earnings Conference
The following is a summary of the NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript:Financial Performance:NeurAxis experienced a decrease in revenues in fiscal year 2023 to $2.5 million, down 8.4
Press Release: NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical
Comments
Timothy Henrichs' appointment could be a game-changer for NeurAxis' strategic commercialization activities. His arrival comes at a crucial growth phase, potentially impacting the company's financial performance and stock value.
Press Release: NeurAxis Appoints Timothy Henrichs as Chief Financial OfficerThe secured funding is essential to accelerate the company's sales and marketing strategies. Additionally, increasing the policy coverage of IB-Stim(TM) and achieving clearance for RED serves as an opportunity to generate meaningful revenues from 2024 onwards.
NeurAxis CMO, Dr. Adrian Miranda, emphasized the economic impact of chronic constipation in the U.S. and the necessity for a screening tool like RED. CEO Brian Carrico sees the University of Michigan agreement as a chance to broaden NeurAxis' adult GI scope.
News
$Neuraxis(NRXS.US$ Press Release: NeurAxis Signs Exclusive Option Agreement With University of Michigan for Innovative Gastrointestinal Device
Dow Jones· 1 min ago
Dow Jones· 1 min ago
$Neuraxis(NRXS.US$ oh ok now! hehehe
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg